Jiangsu Vanguard Pharmaceutical Co.,Ltd.

Primary Study Objective: To evaluate the pharmacokinetic characteristics and bioequivalence of a single oral dose of tadalafil tablets (test formulation, strength: 20 mg, sponsor: Jiangsu Wango Pharmaceutical Co., Ltd.) and reference formulation (trade name: Cialis®, strength: 20 mg, licensee: A. Menarini GmbH) after a meal in healthy adult male subjects in China. Secondary Study Objective: To investigate the safety of tadalafil tablets (test formulation, strength: 20 mg) and reference formulation (trade name: Cialis®, strength: 20 mg) in healthy adult male subjects in China.

Primary Objective: This study used montelukast sodium tablets (10 mg) manufactured and owned by Jiangsu Wango Pharmaceutical Co., Ltd. as the test formulation, and montelukast sodium tablets (10 mg, trade name: Singulair®) owned by N.V. Organon as the reference formulation, in accordance with the relevant regulations for bioequivalence studies, to evaluate the bioequivalence of the test and reference formulations after administration under postprandial conditions. Secondary Objective: To observe the safety of the test and reference formulations, montelukast sodium tablets (trade name: Singulair®), in healthy subjects.

Primary Objective: This study used montelukast sodium tablets (10 mg) manufactured and owned by Jiangsu Wangao Pharmaceutical Co., Ltd. as the test formulation. Montelukast sodium tablets (10 mg, trade name: Singulair®/Singulair®) manufactured by N.V. Organon served as the reference formulation in accordance with relevant bioequivalence study regulations. The study evaluated the bioequivalence of the test and reference formulations after administration in the fasting state. Secondary Objective: To observe the safety of the test and reference formulations, montelukast sodium tablets (trade name: Singulair®/Singulair®), in healthy volunteers.